Business
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n\n\n\nTetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients\nPR Newswire\nOTTAWA, ON, Sept. 6, 2022\n\n\n\nTetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 400MG (Favipiravir)Companies will jointly develop a combination therapeutic candidate for rapid clearance of COVID-19 infectionThe partnership aims to accelerate the global development of an innovative drug candidate to combat viral diseases by leveraging expertise and resources from both companiesThis novel combination therapy is positioned to compete with Pfizer's flagship antiviral therapeuticOTTAWA, ON, Sept. 6, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. (\"Tetra\" or the \"Company\") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC (\"Cellvera\"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.   \n\n \n \n \n \n \n \n\n \nAs a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following SARS-CoV-2 infection in the humanized ACE2 mouse model. ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators (i.e., cytokines) involved in hyperinflammation and immune system dysfunction following viral infection. Other studies have also demonstrated dose-dependent inhibition of viral replication.\nCellvera owns the rights to the brand originator Favipiravir, which has a long and verified history of safety and efficacy and was initially developed by FujiFilm Toyama Chemical Co and approved in Japan (2014) to treat pandemic influenza. Favipiravir is a selective inhibito...